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Abstract: Tumor-targeted drug-loaded nanocarriers represent innovative and attractive tools for
cancer therapy. Several magnetic nanoparticles (MNPs) were analyzed as potential tumor-targeted
drug-loaded nanocarriers after functionalization with anti-Met oncogene (anti-Met/HGFR) monoclonal
antibody (mAb) and doxorubicin (DOXO). Their cytocompatibility, stability, immunocompetence
(immunoprecipitation), and their interactions with cancer cells in vitro (Perl’s staining, confocal
microscopy, cytotoxic assays: MTT, real time toxicity) and with tumors in vivo (Perl’s staining)
were evaluated. The simplest silica- and calcium-free mAb-loaded MNPs were the most
cytocompatible, the most stable, and showed the best immunocompetence and specificity.
These mAb-functionalized MNPs specifically interacted with the surface of Met/HGFR-positive
cells, and not with Met/HGFR-negative cells; they were not internalized, but they discharged in
the targeted cells DOXO, which reached the nucleus, exerting cytotoxicity. The presence of mAbs
on DOXO-MNPs significantly increased their cytotoxicity on Met/HGFR-positive cells, while no
such effect was detectable on Met/HGFR-negative cells. Bare MNPs were biocompatible in vivo;
mAb presence on MNPs induced a better dispersion within the tumor mass when injected in situ
in Met/HGFR-positive xenotumors in NOD/SCID-γnull mice. These MNPs may represent a new
and promising carrier for in vivo targeted drug delivery, in which applied gradient and alternating
magnetic fields can enhance targeting and induce hyperthermia respectively.
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1. Introduction
Despite the substantial advancements both in diagnosis and therapy, cancer is still the second
cause of morbidity and mortality in western countries, although great advances have been observed
both in diagnosis and therapy [1]. Chemotherapy, one of the most important conventional cancer
therapies, suffers from several limitations, such as lack of specificity and drug-associated side effects,
which can be particularly severe as the well-known cardiotoxicity of anthracyclines [2–4]. In the field of
nanotechnology, nanoparticles (NPs), in particular, which may overcome these drawbacks are actively
studied and applications have started to be found [5]. Indeed, thanks to their nanometric dimensions,
and thus their high surface to volume ratio, nanocomplexes can be very efficient multifunctional
platforms for what is called presently theranostics, acting not only as drug delivery systems, but
also for tumor imaging, and tracking with fluorophore and other molecules to follow the disease
and its treatment [6–11]. Moreover, NPs can increase drugs bioavailability and protect them from
degradation [12]. More importantly, they can exert tumor targeting activity, both passive and active,
minimizing the drug-associated adverse side effects and increasing the therapeutic index [6,13].
Concerning active targeting, magnetic nanoparticles (MNPs) present the inherent physical
properties of being able to respond to an applied magnetic field, which can direct them on the targeted
tumor site, where they can release their payload [14]. MNPs can also respond to an alternating magnetic
field, developing hyperthermia, which can be exploited for thermoablation of cancer cells [15–17].
Moreover, MNPs can be used in magnetic resonance imaging (e.g., as contrast agents), cell transfections,
and also for in vivo cell tracking and tissue repair [10,18,19].
MNPs are generally obtained by chemical synthesis, more often by coprecipitation of Fe2+ and
Fe3+ ions in a basic aqueous media (e.g., NaOH or NH4OH solutions). The small magnetic core based
on iron oxide (Fe3O4 herein named M) can be coated with a shell, with the goal of stabilizing the MNP,
avoiding their aggregation and adding functionalities [11,20,21]. MNPs smaller than 30 nm generally
display superparamagnetic properties [12].
Active tumor targeting can be pursued also by engrafting drug-loaded NPs with probes recognizing
specifically tumor-associated markers expressed at the cell surface. This is the evolution and the
improvement of the immunotoxins and antibody-drug conjugates, which first realized the concept of
“magic bullet” [22,23], since NPs can carry significantly higher amounts of both targeting moieties and
chemotherapeutics, and thus are more efficient, displaying higher avidity for the targeted tumor cells [24–26].
Receptors for growth factors are among the most used targetable tumor-associated markers, as
they are often overexpressed on tumor cells, since their overexpression maybe pivotal and responsible
for the uncontrolled proliferation of tumor cells. Well-known examples are the folate receptor [27],
the transferrin receptor [28], the tyrosine kinase receptors, such as for epidermal growth factor HER2,
and hepatocyte growth factor [29–32]. The latter is encoded by the Met oncogene (Met/HGFR) and is
overexpressed in many tumors and involved also in the metastatic process [31–33]. Different types of
targeting ligands can be used; monoclonal antibodies (mAbs) or their fragments and growth factors
are among the most common [24,27,28], but also peptides [34,35] and aptamers [36,37] are used.
In this study, different types of MNPs (uncoated or coated with silica, undoped or doped with
calcium) were studied with the aim of selecting the best one for in vitro and in vivo experiments
after functionalization with monoclonal antibodies against the Met/HGFR as targeting moieties
and with doxorubicin (DOX0), a commonly used chemotherapeutic drug. Different properties and
parameters were taken into account for selection at different subsequent steps, as shown in Figure 1.
We show that uncoated and undoped MNPs are the best performing. Moreover, mAb-functionalized
MNPs specifically interact with the surface of Met/HGFR-positive GTL-16 cells, and not with
HGF-R/Met-negative Huh7 cells. The presence of the mAbs on DOXO-MNPs (mAb-DOXO-MNPs)
significantly increased the toxic activity on GTL-16 cells, whereas no such effect was detectable on
Huh7 cells. MNPs were biocompatible when injected in mice and the presence of the mAb on MNPs
enhanced their retention (in the tumor) when injected in situ in GTL-16 cells induced xenograft tumors
in γ-null mice.
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2. Materials and Methods
2.1. Materials
Unless otherwise specified reagents were purchased from Sigma-Aldrich, St. Louis, MO,
USA. DMEM high glucose (L-glutamine 4 mM, glucose 4500 mg L−1) and phosphate buffer saline
(0.0067 M, none of calcium and magnesium), fetal calf serum (FCS), annexin V-FITC and horseradish
peroxidase-conjugated affinity purified rabbit anti-mouse IgG antibodies were purchased from Thermo
Fisher (Waltham, MA, USA). Enhanced chemiluminescence (ECL kit) from Biorad (Hercules, CA,
USA); and polyvinyl fluoride membranes for western blot from GE Healthcare Life Science (Chicago,
IL, USA). TRITC-phalloidin, FITC-labelled rabbit anti-mouse Ig and TO-PRO-3 were purchased from
Life Technologies (Carlsbad, CA, USA). All reagents were of analytical purity and used without
further purification.
2.2. Synt esis of Sup paramagnetic Iron-Oxide Nanoparticles
MNPs were synthetized as already described [38,39]. All the MNPs described consisted of a core
of iron oxide, obtained by a co-precipitation method mixing aqueous solutions of FeCl2·4H2O and
FeCl3·6H2O 0.01 M to obtain a stoichiometric ratio of Fe2+/Fe3+ of 1:2, with the addition of NH4OH.
Citric acid (0.05 M) was added and adsorption was carried out at 80 ◦C, before the last washing to
improve the MNPs dispersion in water. Coating with Silica and doping ith calcium were also carried
out in view of a possible improvement of MNP ater dispensability and greater potential for their
further functionalization [20,38]. In particular, some MNPs were coated with a silica shell (MSNPs)
following the Stöber method [40], by the addition of a mixture of tetraethyl orthosilicate (TEOS) as
silica precursor, ethanol and water (with an ethanol:water ratio of 1:1). Finally, some MNPs were also
prepared, after TEOS functionalization, in the presence of calciu citrate (MSCaC-NP) or calcium
hydroxide (MSCaH-NP), reaching a very low Si:Ca ratio (99:1), to avoid particles agglomeration and
toxic effect towards cells, but to enhance surface reactivity [41,42].
2.3. Functionalization of Nanoparticles
Magnetic nanoparticles were functionalized with DOXO and with the DO-24 monoclonal antibody
(mAb), an IgG2a/k mAb produced against the ectodomain of the human Met/HGF receptor [43,44]
by isothermal adsorption, as already described [45]. Experiments were performed to assess the
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maximum amount of mAb and/or DOXO loaded on the nanoparticles separately and in combination
by mixing 5 mg of MNPs with 1 mg/mL of DOXO dissolved in water or of purified mAb dissolved
in Hepes buffered saline solution (0.01 M Hepes, 0.15 M NaCl). Mixtures were shaken at 200 rpm at
25 ◦C for different periods of time up to 24 h in Eppendorf tubes. DOXO and mAb contents were
assessed by UV-Vis spectroscopy (λ = 495 and 280 nm, ε = 10,650, and 64,000 M-1 cm−1, respectively;
Nanodrop 2000, ThermoScientific). The amounts of the adsorbed molecules were calculated from the
differences between the concentrations of the molecules in solutions before and after the adsorption
on MNPs (the so-called supernatants). The solid components were washed many times with Hepes
buffered saline solution until the absorbance was less than 0.02 absorbance arbitrary units at 490 or at
280 nm (equivalent to a negligible amount) using a magnet to avoid removing the MNPs. Then, the
functionalized nanoparticles were resuspended in Hepes buffered saline solution and kept at 4 ◦C until
their use. In the case of MNPs conjugated with both moieties (mAb and DOXO, the so-called ternary
nanoparticles), the same protocol was sequentially applied, each time followed by extensive washings,
DO-24 mAb coupling first and DOXO coupling in the second step, based on previous experiments of
the group [9,45].
2.4. Characterization of Nanoparticles
The stability of the functionalized MNPs was monitored by incubating them in phosphate
buffered saline (PBS) containing 10% fetal calf serum (FCS) or not for different periods of time (from
1 to 7 days, two samples for each time) under constant stirring (200 rpm) at 37 ◦C. In the case of
DOXO-functionalized NPs, supernatants were, then, separated from the solid components by a magnet
and analyzed by UV-Vis spectroscopy, as described above and the released amounts were referred to
as a percentage of the amounts that were adsorbed initially. The stability of the mAb-functionalized
nanoparticles was assessed directly on the NPs recovered by the magnet and the mAb bound on them
was estimated in SDS-PAGE and WB.
The size distribution of MNPs was evaluated by dynamic light scattering (DLS) measurements,
using a Zetasizer Nano-ZS instrument (Malvern Instruments, Worcestershire, UK) equipped with
a 4 mW He-Ne laser operating at 633 nm and a detection angle of 173◦. For the measurements, the
materials were suspended (0.1 mg/mL) in PBS (pH 7.4). Hydrodynamic diameters are reported as
number distribution and expressed as mean value± standard deviation of three separate measurements,
each resulting from 14 runs.
The ζ potential of the MNPs was measured by electrophoretic light scattering (ELS), using a
ZetasizerNano-ZS (Malvern Instruments). For the measurements, the materials were suspended
in MilliQ water at the concentration 0.1 mg and for each sample five measurements were carried
out, each resulting from 10 runs. The ζ potential values are, therefore, expressed as mean value ±
standard deviation.
The immunocompetence of the mAb-functionalized MNPs was assessed by incubating them with
clarified detergent extracts prepared from GTL-16 (Met+) cells and Huh7 (Met–), as negative controls,
in DIM buffer (50 mM PIPES pH 7.4, 300 mM saccharose, 100 mM NaCl, 5 mM EGTA, 5 mM MgCl2,
and 100 µM ZnCl2), 1% Triton X-100, 1 mM TRIS HCl pH 8.8, and a cocktail of protease inhibitors) at
4 ◦C overnight, as described [45]. MNPs were then washed three times by the use of a magnet, proteins
were solubilized, heated at 95 ◦C, separated in 10% SDS-PAGE, transferred on polyvinyl fluoride
membranes for Western blot and decorated with anti-Met DL-21 mAb [44]. Then filters were reacted
with horseradish peroxidase-conjugated affinity purified rabbit anti-mouse Ig antibodies (RaMIg/PO,
1:5000), reacted with enhanced chemiluminescence (ECL) and analyzed in the Versadoc instrument
(Biorad, Hercules, CA, USA).
Micro-Raman analyses were carried out using a Jobin Yvon HR800 LabRam spectrometer (HORIBA
Jobin Yvon, Paris, France). Instrument calibration was carried out before each analysis by checking the
position and intensity of the Si band at 520.65 + −0.05 cm−1. In order to balance signal against noise, at
least two cycles of 300 s were performed. A D06 filter allowed preventing damages to the samples and
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the confocal hole was maintained at 200 µm to collect signal from the surface of the particles. All the
spectra were collected with an 80× objective, with a 0.75 numerical aperture (N/A), and 1800 gr/mm
diffraction grating. All the physical parameters were fixed during every analysis. Spectral resolution
of the instrument was about 2 cm−1 and the registered spectra were processed by means of the ORIGIN
software v. 6.0 (OriginLab Corporation, Northampton, MA, USA).
2.5. Cell Lines
GTL-16 [46], a poorly differentiated human gastric carcinoma derived cell line which express
Met/HGFR, and Huh7 [47], a well differentiated hepatocyte derived cell carcinoma negative for
Met/HGFR expression, were maintained in Dulbecco’s modified Eagle’s medium (DMEM, Sigma),
supplemented with 10% FCS, 50 U/mL penicillin, and 50 µg/mL streptomycin. Cells were incubated
at standard conditions (37 ◦C, 5% CO2), and passaged when they were at 90% to 95% confluence (at
ratios, GTL-16 of 1:3 and Huh7 of 1:6).
2.6. Cytocompatibility
For cytocompatibility assays GTL-16 cells (12 × 103/well) and Huh7 (6 × 103/well) were incubated
in 100 µL of complete medium, and then, several concentrations of the different nanoparticles or
mAb-functionalized nanoparticles were added in 100 µL of fresh medium [45]. Doxorubicin (DOXO),
1 µg/mL, was used as control of toxicity. After 3 days incubation, cell viability was evaluated by the
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT, Sigma) colorimetric assay. Briefly,
20 µL of MTT solution (5 mg/mL in a PBS solution) were added to each well. The plate was then
incubated at 37 ◦C for 3 h. After the removal of the solution, 125 µL of 0.2 M HCl in isopropanol were
added to dissolve formazan crystals. One hundred µL were then removed carefully and the optical
density was measured using a multi-well plate reader (Multilabel Reader Victor TM X4; PerkinElmer
(Waltham, MA, USA) at 570 nm. Viability of parallel cultures of untreated cells was taken as 100%
viability, and values obtained from cells undergoing the different treatments were referred to this value.
Experiments were performed 4 times using 3 replicates for each sample.
For cytofluorometer assessment of cell death, cells were collected after 72 h incubation with
nanoparticles, washed in PBS, and incubated for 15 min at room temperature with 2 µL of annexin
V-FITC (100 nM) and 5 µL of propidium iodide (PI, 50 µg/mL) dissolved in 93 µL of buffer solution
(10 mM HEPES-NaOH, pH 7.4, 140 mM NaCl, and 2.5 mM CaCl2). At least 10,000 cells were analyzed
in a FACScan flow cytometer (Becton Dickinson, Mountain View, CA, USA) equipped with an argon
laser and the Leica TCS SP2 AOBS Spectral Confocal Scanner microscope. All experiments were
performed in triplicate and repeated at least three times. Data are given as means ± SD. Couples of
conditions were compared with Student’s t-test. The level of significance was p < 0.05.
2.7. Interaction of Magnetic Nanoparticles with Cells and Cytotoxicity of Functionalized MNPs
For Prussian Blue (PB) staining GTL-16 (24 × 103/well) and Huh-7 (12 × 103/well) were seeded on
glass coverslips in 24-well plates and after 24 h presaturated MNPs (in 0.4% BSA at 37 ◦C for 2 h), either
not functionalized or mAb-functionalized, were added (100 µg/mL). After the incubation at 37 ◦C for
2 h, coverslips were washed with fresh PBS pH 7.2, fixed with paraformaldehyde (4 wt. % in PBS) and
rinsed in PBS. Then, they were stained with Prussian Blue solution (1:1 of 2% potassium ferrocyanide
and 2% HCl both in H2O) for 15 min, as described [38]. After washing with fresh PBS, nuclear fast red
was added to stain cell nuclei. Coverslips were then washed with H2O and were mounted on slides
with Eukitt quick-hardening mounting medium. Samples were analyzed by optical microscopy.
Alternatively, fixed samples were processed for confocal microscopy analysis. For this they were
permeabilized with TRIS-buffered saline (TBS) containing 5% bovine serum albumin (BSA, Sigma), 0.1%
Triton-X100 and 5% goat serum and then stained for 1 h, as described [45]. Cytoskeletal actin was stained
with TRITC-phalloidin (1/200, excitation at 543 nm, and emission at 560–620 nm), or FITC-phalloidin
(excitation at 488 nm and emission at 500–535 nm), mAbs with FITC-labelled rabbit anti-mouse IgG
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(1/100, excitation at 488 nm, and emission at 500–535 nm) and nuclei with TO-PRO-3 (1/70, excitation at
633 nm and emission at 650–750 nm). DOXO was detected after excitation at 476 nm and emission at
575–630 nm. At the end of the incubation, slides were rinsed and mounted. Fluorescence was detected
using the Confocal Scanner microscope. Images were taken at 630×magnification.
For cytotoxicity experiments performed with the xCELLigence® instrument (RTCA system;
ACEA Biosciences Inc., Santa Clara, CA, USA) cells (approximately 12 × 103 GTL-16/well or
6 × 103 HuH-7/well) were seeded on appropriate micro-well plates for 24 h. From this time on,
the impedence was monitored (time 0 of the experiment), and the not functionalized or the differently
functionalized MNPs (100 µg/mL) were added in 100 µL of medium. Equimolar amounts of DOXO,
either soluble or loaded on nanoparticles were used. Cell cultures were monitored up to 3 days.
2.8. In Vivo Distribution of MNPs
All procedures were approved (Ministero della Salute: #178/2019-PR) and carried out in accordance
with the Animal Care and Use Committee of UPO, the European Community Directive for Care and
Italian Laws on animal experimentation (Law by Decree 116/92). Mice were purchased from Charles
River (Calco, Lecco, Italy) and housed under standard conditions in a pathogen-free environment.
Three 8-to-10-week old NOD/SCID-γnull (NSG) female mice were injected in the tail vein with
10 µg/g mouse diluted in a final volume of 100 µL of sterile PBS. After 3 days these mice, together with
untreated control mice, were euthanized and their organs were collected, fixed, embedded in paraffin,
and processed for histological analysis. Serial sections were stained with Prussian blue, counterstained
with nuclear fast red and subjected to histological evaluation by an independent pathologist not
informed of the sample identity.
2.9. In Vivo Injection of MNPs in Tumor-Bearing Animals
For tumor formation 2× 106 human GTL-16 cells/mouse were resuspended in PBS, subcutaneously
injected and allowed to grow up to 7–10 days (tumor size was around 0.5 × 0.5 cm). Fourteen mice
were then subdivided in two groups and injected intratumorally with either not functionalized MNPs
or mAb-functionalized MNPs (10 µg MNP/g mouse). A third group of five animals, in which tumor
was induced, remained untreated. Mice were then euthanized 3 days after; tumors were collected,
processed for histological and iron content analysis (Prussian blue staining). The % of blue Prussian
staining and standard area from 5 randomly chosen areas from each of the 3 tumor sections (100 microns
apart) for each of the 7 tumors (n = 105) were analyzed with ImageJ software.
2.10. Statistical Analysis
Data are expressed as mean ± standard error of at least 3 triplicates. Statistical analyses were
performed using a one-way ANOVA with Bonferroni’s post-test for grouped analyses using GraphPad
Prism version 4.03 for Windows, GraphPad Software (GraphPad Prism, San Diego, CA, USA).
One representative experiment out of the three performed is shown, except for the experiments carried
out in vivo. Statistical analysis of the presence of nanoparticles in tumor sections was performed using
unpaired t test and F test for unequal variance on the measures obtained. The results are shown as
box and whisker plots, showing the minimum, first quartile, median, third quartile, and maximum
measures. Differences at p < 0.05 were statistically significant. Statistical differences between the
treatments were considered significant when p values were p < 0.05, p < 0.01, p < 0.001, labelled in the
figures as *, **, ***, respectively.
3. Results and Discussion
3.1. Cytocompatibility of Magnetic Nanoparticles
The cytotoxicity of nanocarriers is a key factor for their eventual potential biomedical applications.
Therefore, the four types of NPs, already characterized and used in different systems [38,39], were
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tested for their cytocompatibility on the GTL-16 human gastric carcinoma cell line, in view of their
further use in in vivo experiments after functionalization with a targeting mAb. Cells were incubated
with increasing doses of MNPs (from 6.25 µg/mL to 50 µg/mL) for 72 h and analyzed by MTT assays.
In these static exposure conditions, a slight reduction in cell viability was observed in a dose-dependent
manner (Figure 2a), which, however, was always higher than 80%. Indeed, these values are above the
cytocompatibility cut-off (70%) indicated by ISO 10993-5:2009 [48]. The same results were observed
when the L929 normal fibroblast cell line was incubated with the four types of MNPs (not shown).
Cytocompatibility was also assessed in an annexin V/propidium iodide test, which was able distinguish
between apoptotic and necrotic cells. In this case, pure MNPs, as well as MNPs covered with a
Silica shell (MSNPs), behaved as in the MTT assay, while both types on MNPs doped with calcium
(MSCaC-NP and MSCaH-NP) induced a significant level of apoptosis (ca. 15% and 20%) and necrosis
(22% and 20%), when used at the highest concentrations (Figure 2b). Different results were observed
for calcium-doped MNPs which can be accounted for by the fact that the two assays measured
different parameters, the former an enzymatic activity of the mitochondrion, the latter a biochemical
modification of the external cell surface occurring precociously in apoptosis [49]. The detrimental effect
exerted by calcium can be ascribed to the fact that the level of this ion controls many biological activities,
and thus must be finely tuned both in the extracellular and in the intracellular environments [50].
An uncontrolled increase in its levels might be cytotoxic, by inducing oxidative stress, and thus
promoting cellular apoptosis and necrosis [51]. Thus, on the basis of these cytocompatibility assays,
the two best performing nanoparticles (MNPs and MSNPs) were selected for further experiments of
functionalization, discarding the two MNPs containing calcium.
3.2. Functionalization of Magnetic Nanoparticles
Functionalization was carried out with the DO-24 mAb, which recognizes the ectodomain of the
human Met/HGFR, which is overexpressed at the surface of many tumors [32,52] and with DOXO,
which is one of the most used chemotherapeutic drugs. The two molecules were bound via isothermal
adsorption, to better preserve the biological activity of the mAb. Coupling of the mAb to both
nanoparticle types was efficient since the first incubation time assessed, with values of about 35% and
46% of the initially incubated mAbs to MNPs and MSNPs, respectively (Figure 3a), resulting in 70 to
92 µg mAb bound/mg NP. In the case of DOXO, the maximum binding was reached with a certain delay
(after 4 h incubation for MSNPs and 8 h incubation for MNPs) and no significant differences in the
bound amounts (96% ± 0.05 in the case of MNPs and 99% ± 0.06 in the case of MSNPs, corresponding
to nearly 200 µg Doxo bound/mg NP) were observed (Figure 3b). This very high percentage can be
explained based on the properties of the DOXO molecule, which carries both negative and positive
charges and has the propensity to form dimers in solution [53] and can potentially be adsorbed on
multiple layers on NPs. This would also explain the observed delay in reaching the plateau. The fact
that a lower percentage of the mAb bound to the MNP surface can also be ascribed to the steric
hindrance it exerts, because it has a molecular mass approximately 275-fold than that of DOXO.
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Figure 3. Functionalization of magnetic nanoparticles and stability of the complexes. Nanoparticles
were incubated for different times under constant stirring (200 rpm) at 37 ◦C with DO-24 monoclonal
antibodies (mAbs) (a) or doxorubicin (DOXO) (b) for isothermal adsorption. The washed complexes
(mAb-NPs, c and e and DOXO-MNPs, d and f) were then incubated for different times under constant
stirring (200 rpm) at 37 ◦C in PBS not containing (c,d) or containing (e,f) 10% FCS. The particulate and
the soluble fractions were separated through a magnet and mAb bound on nanoparticles was estimated
in SDS-PAGE and WB (A), while DOXO bound was calculated by subtracting the amount detected in
the soluble fraction (B). For statistical analysis the treatments were compared between each other at
each time point (*** p < 0.001).
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3.3. Characterization of Magnetic Nanoparticles
The stability of the different complexes, in which the functionalizing moieties are bound by
electrostatic interactions, was then analyzed by evaluating the amount of the two ligands remaining
bound to nanoparticles after incubation in PBS at 37 ◦C in continuous stirring for different times up to
seven days. The two immunocomplexes behaved similarly up to three days incubation with no release
of mAb (Figure 3c). However, after this period more than 50% of the adsorbed mAb was released from
MSNPs, while none from MNPs. In the presence of 10% FCS, mAbs were released more precociously
from both MNPs types (Figure 3e) and also, in this case, MNPs performed better than MSNPs, because
only 10% of the adsorbed mAb was released from the former after three days vs. 50% from the latter
after only one day. For longer times, mAb release from both NP types increased, but at lower levels in
the case of MNPs. The stability of mAb-MNPs for three days in the presence of 10% FCS should be a
time long enough to allow them to reach their targeted molecules on tumor cells. The stability of the
immunocarrier could be improved by covalent binding of the mAb, but this would inevitably involve
more complex synthetic procedures and the introduction of some chemical reagents with potential
toxicity problems [54]. It was also reported for one case in which DOXO was therapeutically active
when it was noncovalently entrapped in the nanoconstruct, but not when it was coupled via covalent
amide bonds [55].
In the case of DOXO-functionalized nanoparticles, less than 2% to 2.5% of the bound
chemotherapeutic was desorbed from both types of NPs in PBS, and less than 10% was released after
incubation in the presence of FCS, suggesting highly stable complexes in all cases (Figure 3d,f). When
DOXO was coupled to mAb-functionalized MNPs, about 40% of the input amount was adsorbed and
also, in this case, only 2% to 2.5% of the bound DOXO was released (not shown).
The two immunocomplexes, obtained by coupling of MNPs and MSNPs, respectively, were then
tested for their cytocompatibility on GTL-16 in an MTT assay performed after three days incubation.
The mAb-MNPs were highly cytocompatible, because more than 95% of the cells were fully viable at
the highest dose used of 50 µg/mL, whereas, in the case of mAb-MSNPs, cell viability was somehow
decreased (lower than 80%), in line with the results and values observed for not functionalized MSNPs
(Figure 4). Thus, also from this point of view, MNPs displayed better properties.
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Figure 4. Cytocompatibility of the mAb-functionalized magnetic nanoparticles. Viability of GTL-16
cells was assessed in MTT assays after three days incubation. Data are expressed as % cell viability
with respect to control untreated cells. For statistical analysis all data were compared vs. untreated
samples (*** p < 0.001).
The ability of the mAb-functionalized magnetic NPs to react with the cognate antigen, i.e., their
immunocompetence, was assessed in immunopre ipitati n experiments with xtracts from cells
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expressing the Met/HGFR antigen or not. Only the MNPs coupled with the mAb, but not the MNPs
devoid of the mAb, were able to precipitate a 145 kDa band, corresponding to the Met/HGFR β chain,
from samples obtained from the Met/HGFR+ GTL-16 cells (Figure 5a, lanes 4 and 8 vs. lanes 3 and
7). The capability to immunoprecipitate Met/HGFR is not the same among the functionalized MNPs,
since mAb-MNPs appeared to display a better activity than mAb-MSNPs in terms of interaction with
the antigen. The 145 kDa band could not be detected in the immunoprecipitation performed with
mAb-coupled MNPs reacted with extracts from Huh7 cells, which do not express Met/HGFR. In these
cases, only the 55 kDa band, corresponding to the mAb heavy chain, were visualized (Figure 5a,
lanes 6 and 10) and, as expected, no bands were detected when the precipitation was performed with
MNPs devoid of mAbs (Figure 5a, lanes 5 and 9). All together these data support the specificity of the
mAb-MNPs. The same experiment was performed also incubating ternary MNPs with GTL-16 cell
extracts. In this case, no differences were detected in the ability of mAb functionalized MNPs either
carrying DOXO or not (Figure 5b, lanes 4 and 6 vs. lanes 3 and 5), showing that DOXO adsorption
did not impair the immunocompetence of mAb-loaded MNPs. Moreover, these data suggest that,
in all the cases, the Fab domains of the mAb should be exposed externally, possibly in an end-side
orientation imposed also by the steric hindrance of the Fabs relative to the Fc domain, in agreement
with the theoretical work of Sidorov [56] and similar published data [45,57]. In both series of these
experiments, the Met/HGFR was precipitated also by mAb adsorbed on Sepharose Protein G, which is
the gold standard condition for immunoprecipitations (Figure 5a,b, lane 2 vs. lane 1) and no bands
were detected when not functionalized nanoparticles were used.
After all these experiments, including cytocompatibility, stability, and immunocompetence, MNPs
appeared to be the best performants, and thus they were selected for further studies (Figure 6).
MNP and mAb-MNPs underwent further characterization. They were characterized for their
sizes with DLS measurements in PBS. The usual size of these MNPs is around 10 nm to 13 nm, showing
the tendency to form agglomerates of different sizes (Table 1), as already reported in the literature for
this type of compounds [58,59]. It is worth noting that most of the agglomerates of bare MNPs (97%)
are of size fully compatible with the interaction with cells. Further functionalization of MNPs with
mAb and DOXO slightly perturbed the agglomerates distribution, even if smaller agglomerates remain
predominant. The ζ potential value determined for MNPs (−18.55 ± 0.86 mV) is in accordance with
literature data [60,61]. The functionalization impacted on the ζ potentials, which turn positive after
DOXO and Mab coupling [62].
The Raman spectrum of the not functionalized MNPs is characterized by a signal at 670 to 707 cm−1
(Figure 7a), typical of Fe3O4 [63]. An additional intense signal at 1648 cm−1 is ascribable to HOH
bending mode of water molecule, whereas other minor signals are present due to stretching modes
of phosphate species [64] of the PBS buffer. In the Raman spectrum of mAb functionalized MNPs
(Figure 7b), in addition to the signal of Fe3O4 at 670 to 707 cm−1, signals in the 1000–1500 cm−1 range
are also present and they are ascribable to the amide groups of the mAb [45].
Table 1. Properties of magnetic nanoparticles (MNPs).
Acronym Particle Size * (%) Zeta Potential (mV)
MNPs 101 ± 15 (97%) 1229 ± 288 (3%) −18.55 ± 0.86
mAb-MNPs 135 ± 19 (86%) 815 ± 200 (14%) 9.26 ± 0.93
DOXO-MNPs 145 ± 21 (78%) 790 ± 180 (22%) 5.4 ± 0.24
mAb-DOXO-MNPs 132 ± 35 (84%) 654 ± 82 (16%) 8.8 ± 0.55
* nm.
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Figure 5. Immunocompetence of the functionalized magnetic nanoparticles. Nanoparticles differentially
functionalized were incubated with detergent extracts from GTL-16 (Met+) or Huh7 (Met−) cells;
bound proteins were analyzed in SDS-PAGE and WB with anti-Met antibodies and secondary
peroxidase-labelled anti-mouse IgG tib di s. Only, when the mAb and GTL-16 extracts re incubated
together, could a and wit 145 kD molecular weight b detected, corr sponding to the Met proteins,
lanes 2, 4, and 8 in panel (a) and lanes 2, 4, and 6 in panel (b). When mAb was present in the incubated
mixtures, a band 50 kDa, corresponding to the mAb heavy chain, was detectable (even lanes from #3).
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Figure 7. Characterization of mAb-functionalized magnetic nanoparticles. Raman spectra of not
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3.4. Interaction of mAb Functionalized Magnetic Nanoparticles with Cells
The interaction of these MNPs with cells after incubation at 37 ◦C for 2 h was evaluated by
Prussian blue staining, which tracks magnetic nanoparticles as blue dots. The mAb-MNPs were clearly
detectable at the surface of Met/HGFR+ GTL-16 cells, due to the presence of the DO-24 mAb, whereas
MNPs devoid of the mAb were visible at significantly lower levels (Figure 8a, top row). The same low
level of detectability was also found when the mAb-functionalized or not functionalized MNPs were
incubated with the Met/HGFR- Huh7 cells, where also a more random distribution of the few MNPs
was visualized (Figure 8a, bottom row). These data show that the DO-24 mAb coupled MNPs are able
to specifically interact with the cells expressing the Met/HGFR tumor marker; in these conditions these
functionalized MNPs do not appear to be able to be internalized within cells, most probably because
they form agglomerates.
The interaction of the mAb-MNPs with cells was evaluated by also tracking the mAbs in
indirect immunofluorescence experiments examined in confocal laser scanning microscopy (Figure 8b).
The signal due to the FITC-conjugated secondary antibody was evident only when mAb-functionalized
MNPs wer incubated with GTL-16 cells (Figure 8 , f t ). s in the case of the experiments
perfo med with Prussian blue staining, also in this case, MNPs, which were made detectabl in indirect
way, were present at th cell surface, but they were not internalized within cells. By contrast, in samples
where soluble mAbs were incubated with GTL-16 cells, mAbs w re found within the cells, s ce a ye low
signal w s detectable, resulting from the perimposition of the tw signals, t green corresponding to
the mAb and the red to the cell cytoskeleton (Figure 8b, second row). Finally, n signal was detectable
when this kind of experiment was performed on Huh7 cells (Figure 8b, right column) or on both cell
targets with not functionalized MNPs (Figure 8b, third row). Thus, these data agree with and confirm
the results obtained with Prussian blue staining. They show a mAb-dependent and specific interaction
of the MNPs with cells targeted by the mAb. In this context, additionally, it should be considered that
in vivo the mAb-functionalized MNPs would bind preferentially to cells expressing higher amounts of
the recognized marker, such as tumor cells, among all the cells they encounter [45].
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Figure 8. Interaction of mAb-functionalized magnetic nanoparticles with cells. GTL-16 and Huh7 cells
were incubated with MNPs, functionalized or not with the DO-24 mAb (a) and (b), as well as with
soluble mAb (b) for 2 h at 37 ◦C. After washing, staining was performed with Prussian blue (a); the
first th ee panels on the left are 200×magnificati the forth on the right is 400×magnification for
both cell types) or with FITC-labelled anti-mo ( reen), TRITC-lab lled falloidin (red), TO-PRO3
(blue) to label the DO-24 mAb, the cytoskeletal a ti nuclei, respectively (b). Imag s were then
merged. CTRL−, control untreated cells.
In another set of experiments ternary MNPs functionalized with both mAbs and DOXO were
incubated with GTL-16 cells for 2 h. In this case, too, mAbs were detected at the surface of the cells
labelled in green by FITC-coupled secondary antibodies, but the red fluorescent DOXO was found in the
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cell nuclei, strongly suggesting that it was discharged from MNPs, internalized and able to reach nuclei,
where it could eventually exert its toxic activity (Figure 9, fourth row). In the same series of experiments,
when cells were incubated either with soluble DOXO (Figure 9, second row) or with DOXO-functionalized
MNPs (Figure 9, third row), this drug was detectable in the nuclei, but at clearly lower levels in the latter
case. It is thus shown that the presence of mAb on DOXO-functionalized MNPs enhances the cellular
uptake of the drug. While DOXO is discharged intracellularly, the mAb was found only extracellularly
associated to the cells surface, possibly because the former was present in a more external position on
the nanoparticle as compared with DO-24 mAb which was adsorbed first. The fact that in vivo tumor
microenvironment is generally acidic (pH < 6) would favor the dissociation of DOXO from MNPs.
Indeed, at these pH values the strength of the electrostatic bonds between the particle and the adsorbed
molecules should be decreased, facilitating desorption. In these conditions it cannot be excluded that
a certain amount of mAb could also be released from MNPs in vivo in the tumor cells environment,
however, once in this site, the mAbs should have already performed their targeting activity.
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Figure 9. Interaction of mAb-DOXO-functionalized nanoparticles with GTL-16 cells. Cells were
incubated with mAb-functionalized MNPs, carrying or not DOXO, as well as with soluble DOXO for 2
h at 37 ◦C. After washing, staining was performed with FITC-labelled anti-mouse Ig (green), TO-PRO3
(blue) to label the DO-24 mAb and nuclei, respectively. DOXO is detected as a red signal. Images were
then merged.
3.5. Enhanced Cytotoxicity of mAb-Functionalized DOXO-Loaded MNPs on Specifically Targeted Cells
Next, the toxicities exerted by the binary MNPs functionalized with DOXO and that of the ternary
MNPs also carrying the targeting mAb were compared in an xCELLigence® assay performed on
GTL-16 cells. A significant difference (p < 0.001) was observed, because the presence of the mAb on
MNPs strongly increased the toxicity on GTL-16 cells in respect to that displayed by binary MNPs both
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at 24 and 48 h (Figure 10a). Indeed, in the former case, the level of toxicity is superimposable to that
of soluble DOXO, while that of binary DOXO-MNPs is significant lower, in line with what already
has been reported for other nanoparticles [45,57]. In parallel control experiments performed on Huh7,
which do not express the relevant marker, no differences in the toxic activities of the ternary versus
the binary MNPs were observed and, in any case their toxicity was lower than that of soluble DOXO
(Figure 10b). Thus, MNPs allow decreasing the aspecific DOXO cytotoxicity and, if functionalized
with the mAbs, allow focusing it on targeted cells, sparing cells, which do not express Met/HGFR.
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with these same MNPs in a different mouse strain [38]. No distress signals were observed at day 
three, as well as after one month, the latest time point analyzed. No obvious organ damages or toxic 
side effects were observed after Prussian blue staining of the histological sections performed at day 
three (Figure 11). At the dose of MNPs used, only spleens showed significant blue deposits, whereas 
lung, liver, and kidney were stained at significantly lower levels, suggesting minimal deposits of 
MNPs. No iron signal could be detected in the heart and in the brain (data not shown). These data 
Figure 10. Cytotoxicity of mAb-DOXO-functionalized nanoparticles. Real-time toxicity of the not
functionalized MNPs, of the MNPs functionalized only with DOXO, or only the mAb or with both
DOXO and mAb were performed on the Met/HGF-R+ GTL-16 and on the Met/HGF-R- Huh7 cells.
The presence of the DO-24 mAbs significantly increase the toxic activity of the DOXO-functionalized
MNPs on GTL-16 cells (a), whereas it had no effect on Huh7 cells (b). Cell index, indicative of cell
viability, was measured in a xCELLigence® assay. CTRL−, control untreated cells. Incubation with not
functionalized MNPs gave results similar to those of the control untreated cells.
All together these data show the positive effect and the specific activity of the mAb coupled
on MNPs on cells expressing the corresponding targeted receptor. NPs were shown to enhance the
anti-tumor activity of the bound anti-Met nanobodies also with another mechanism. In this case,
crosslinked albumin NPs decorated with these nanobodies were better uptaken by cells and were more
efficient than soluble nanobodies in downregulating the Met receptor and inhibiting cell motility [65].
3.6. In Vivo Distribution of Bare MNPs
Before in vivo experiments with tumors-bearing mice, the biocompatibility and the distribution
of not functionalized MNPs was determined in NOD/SCID-γnull mice after systemic administration by
tail vein injection. The dose (10 µg/g mouse) to be injected for these in vivo experi ents was chosen
according t studies previously publishe wit other MNPs [66,67] and previous experience with these
same MNPs in a different mouse strain [38]. No distress signals were observed at day three, as well as
after one month, the latest time point analyzed. No obvious organ damages or toxic side effects were
observed after Prussian blue staining of the histological sections performed at day three (Figure 11).
At the dose of MNPs used, only spleens showed significant blue deposits, whereas lung, liver, and
kidney were stained at significantly lower levels, suggesting minimal deposits of MNPs. No iron
signal could be detected in the heart and in the brain (data not shown). These data demonstrate that,
even if the MNPs have the tendency to form agglomerates, they do not display acute toxicity.
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Figure 11. In vivo distribution of MNPs. NOD/SCID-γnull mice were injected in the tail vein with
MNPs (10 µg/g) in 100 µL PBS. After 3 days these mice, together with untreated control mice, ere
euthanized and their organs were recovered and processed for histological analysis after staining with
Prussian blue. Arrows indicate iron deposits stained in blue.
3.7. Intratumoral Retention of mAb-MNPs Complexes after In Situ Injection
The ability of the mAbs coupled on MNPs to direct their interaction with cells expressing
the Met/HGFR marker was tested in vivo in NOD/SCID-γnull mice bearing tumors induced by
subcutaneously injected human GTL-16 cells and grown until clearly detectable (~0.5 cm Ø, around
day seven to 10). At this time, mice were intratumorally injected with MNPs, either functionalized with
the mAb or not functionalized as the control. MNPs were delivered intratumorally, since in previous
experiments performed with these MNPs coupled with lentiviral vectors, these complexes could not
reach the tumor after MNPs iv injection, even when a magnet was superimposed at the tumor site [38].
This result could be explained by the observation that generally tumors have highly heterogeneous
blood vessel distributions and strong stromal barriers to drug delivery systems [68]. Mice were killed
three days after nanoparticles administration. In both cases, MNPs could be visualized by Prussian
blue staining. Some differences in their distribution patterns were detectable. In the case of mAb
functionalized MNPs, these were detected at higher levels and more spread among the tumor mass,
while in the case of not functionalized MNPs, these showed the tendency to remain closer to the site
of injection (Figure 12). These data indicate that the presence of the mAbs on MNPs allowed them
to reach a higher number of tumor cells and to be retained there. An in vivo tumor targeting effect
of the mAb coupled to MNPs can thus be evinced from these experiments. In addition, in the case
of the MNPs coupled with lentiviral vectors, a targeting effect was observed if NPs were injected
intratumorally and a continuous magnetic field was applied, because more of these functionalized
MNPs were retained there in respect to untreated tumors [38].
These data demonstrate that, in the future, dual targeting could be exploited. In this way the
combination of mAb-dependent chemical targeting and of physical magnetic targeting should enhance
preferential accumulation at the target site [18,69]. Moreover, also at therapeutic level, the tumor could
be attacked by a combined strategy, i.e., chemotherapy and application of an alternating magnetic field
producing heat, to which tumor cells are more sensitive than normal cells (thermoablation), and which
in the meantime enhances drug release from MNPs [15–17,70].
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Figure 12. Distribution of mAb-targeted and not targeted MNPs in Met oncogene positive (Met/HGFR+)
GTL-16 cells induced tumors. NOD/SCID-γnull mice bearing GTL-16 cells induced tumors were injected
intratumorally with MNPs functionalized or not with the DO-24 Ab and killed after 3 days. Tumors
were recovered and processed for staining with Prussian blue. Box and whisker plots summarize the
results obtained from measuring the distribution and quantification of MNPs in the tumors (a). The %
of Prussian blue staining and standard area from 5 randomly chosen areas from each of the 3 tumor
sections (100 microns apart) for each of the 7 tumors (n = 105) was determined. Each plot shows the
minimum, first quartile, median, third quartile, and maximum val es of these % for tumors treated
wit MNPs and mAb-MNPs. Statistical nalyses showed significant differences between the treatments,
with a p < 0.0001 and p < 0.0008 for t and F tests, respectively. Representative tumor sections from mice
r ceivi g not functionalized or mAb- functionalized MNPs (b).
4. Conclusions
The possibility to guide therapeutic molecules on tumor cells by active targeting cell membrane
tumor markers, allowing to decrease the systemic side effects of the drug, is becoming a reality thanks
to ultifunctional nanocarrier platforms. In this study, we coupled magnetic nanoparticles with DOXO
and a monoclonal antibody recognizing the Met/HGFR which is overexpressed on several tumor types
and can thus be considered a tumor-associated marker. Among the different MNPs analyzed, we
found that the simplest ones, made of pure Fe3O4 were the most suitable for our experiments, being
the most cytocompatible, the most stable after functionalization, and the best for Met/HGFR reactivity.
The mAb-functionalized MNPs interacted specifically with the surface of cells expressing Met/HGFR,
they were not internalized, but, when they were also coupled with DOXO, they released DOXO within
the cells and they were more efficient in killing these cells as compared with MNPs coupled only with
DOXO. The aspecific drug cytotoxicity was significantly decreased upon its coupling on MNPs, as
shown on Met/HGFR negative cells.
Finally, when injected in vivo in tumors expressing Met/HGFR, mAb-coupled MNPs were able to
target more efficiently than bare MNPs tumor cells, since they were better dispersed within the tumor
mass. Thus, these MNPs should be considered new and promising nanocarriers for targeted drug
Nanomaterials 2019, 9, 1575 19 of 22
delivery opening new perspectives for in vivo studies, in which continuous and alternating magnetic
fields could be applied to enhance targeting and to induce hyperthermia, respectively.
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